RYALTRIS

This brand name is authorized in Ecuador, Ireland, Israel, Poland, Romania, United Kingdom

Active ingredients

The drug RYALTRIS contains a combination of these active pharmaceutical ingredients (APIs):

1 Mometasone UNII 04201GDN4R - MOMETASONE FUROATE

Mometasone is a topical glucocorticoid with local anti-inflammatory properties. It is likely that much of the mechanism for the effects of mometasone lies in its ability to inhibit the release of mediators of the inflammatory cascade. Read about Mometasone

2 Olopatadine UNII 2XG66W44KF - OLOPATADINE HYDROCHLORIDE

Olopatadine is a potent selective antiallergic/antihistaminic agent that exerts its effects through multiple distinct mechanisms of action. Read about Olopatadine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RYALTRIS Nasal spray, suspension	Health Products Regulatory Authority (IE)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R01AD59		R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AD Corticosteroids
Discover more medicines within R01AD59

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 6166-MEE-0421
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 399706
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9245
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100431398
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W67951001, W67951002, W67951003